local_hospital

Hospital General Universitario De Ciudad Real

Address
lock Available on a paid plan

Cardiovascular Research at Hospital General Universitario De Ciudad Real

This site is active in cardiovascular diseases, with studies focused on conditions such as transthyretin cardiac amyloidosis, spontaneous coronary artery dissection, and genetic carriers of dilated cardiomyopathy. The trials are designed to assess whether new or optimized treatments can better protect heart function and improve outcomes in people at risk of heart failure or acute coronary events.

  • Evaluating heart function in transthyretin cardiac amyloidosis
  • Testing early treatment to prevent dilated cardiomyopathy progression
  • Studying medical therapy for spontaneous coronary artery dissection
  • Improving cardiovascular prevention in inflammatory rheumatic disease

This research reflects a strong interest in both treatment effectiveness and early prevention strategies in cardiology.

Kidney and Immune-Mediated Disease Studies

Clinical trials at this Spanish hospital also address immune system diseases and renal disorders, including lupus nephritis and immunoglobulin A nephropathy. These studies aim to improve kidney response, reduce disease flares, and identify better options for patients with active autoimmune-related kidney disease.

  • Assessing new therapies for lupus nephritis
  • Comparing treatment approaches in proliferative kidney inflammation
  • Evaluating renal response and flare prevention

The work in nephrology and immunology is centered on finding more effective ways to control chronic inflammatory kidney disease.

Oncology and Surgical Treatment Research

The site is involved in neoplasms research across several cancers, including metastatic castration-resistant prostate cancer, upper tract urothelial carcinoma, anal canal squamous cell carcinoma, and peritoneal metastases of colorectal cancer. These trials are exploring whether new drug combinations, radioligand therapy, or surgical strategies can improve cancer control and reduce recurrence.

  • Testing advanced treatment for metastatic prostate cancer
  • Studying chemotherapy planning in upper tract urothelial carcinoma
  • Evaluating combined therapy for anal cancer
  • Assessing recurrence prevention in colorectal cancer spread to the peritoneum

This area highlights a broad effort to refine both systemic and local approaches in oncology.

Respiratory and Critical Care Trials

Research in respiratory tract diseases and acute care includes studies in acute respiratory distress syndrome and septic shock. The main purpose is to determine whether targeted resuscitation or new therapies can improve survival, reduce the need for ventilation, and support recovery in critically ill patients.

  • Investigating treatment for acute respiratory distress syndrome
  • Testing resuscitation strategies in septic shock
  • Improving outcomes in intensive care patients

These trials show a clear focus on critical care medicine and better management of life-threatening conditions.

Allergy, Skin, and Musculoskeletal Research

The trial portfolio also includes skin and connective tissue diseases, musculoskeletal diseases, and selected allergic conditions. Studies are examining improved symptom control for allergic rhinitis, better field treatment for actinic keratoses, and stronger prevention of fractures in older women with bone fragility.

  • Evaluating allergy treatment for rhinitis and related asthma
  • Studying topical therapy for actinic keratoses
  • Comparing treatments to prevent vertebral fractures

This mix of studies combines dermatology, allergy, and bone health research aimed at improving everyday quality of life and reducing future complications.

Anesthesia and Procedure-Related Research

The site also contributes to anesthesia and analgesia research, with work focused on general anesthesia in adults undergoing surgery. These trials are intended to compare approaches that may support safer induction and more reliable perioperative care.

  • Assessing methods for anesthesia induction
  • Comparing options to support surgical care
  • Improving safety in elective procedures

This area adds an important procedural dimension to the broader clinical research program at Hospital General Universitario De Ciudad Real.

Site Overview

assignment
17
connected trials
corporate_fare
16
sponsors
science
59
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
17
Total trials linked
Highly Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 13 therapeutic areas and 15 of 59 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 48 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
10
Sponsors (total)
16
Active sponsors
9

Sponsor Network

Top 9 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 567 other sites in Spain

description
Trial volume
17
Outperforms 78% of sites
public
Therapeutic diversity
13areas
Outperforms 88% of sites
groups
Sponsor diversity
16sponsors
Outperforms 81% of sites

Therapeutic Area Benchmark — Spain

Select a therapeutic area to compare against other sites in Spain.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Spain

Market Share

Country: Spain

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Hospital General Universitario De Ciudad Real

lock Showing 1 of 17 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate CancerCurium Pet FrancePhase IIINot RecruitingFeb 2023

IMP list

lock Showing 1 of 59 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Prednisone2Unknown2023-02-162023-02-20

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.